AAPL328.21+3.25 (+1.00%) ▲|ABBV260.21-1.51 (-0.58%) ▼|ABT108.79-1.68 (-1.52%) ▼|ACN193.12+5.44 (+2.90%) ▲|ADBE285.75+5.96 (+2.13%) ▲|AMAT435.91-2.55 (-0.58%) ▼|AMD456.16-0.90 (-0.20%) ▼|AMGN444.12+1.28 (+0.29%) ▲|AMT177.75+4.83 (+2.79%) ▲|AMZN258.90+3.92 (+1.54%) ▲|AVGO357.16-10.08 (-2.74%) ▼|AXP329.82-0.16 (-0.05%) ▼|BA210.51+1.64 (+0.79%) ▲|BAC63.04+0.44 (+0.70%) ▲|BKNG195.13-4.47 (-2.24%) ▼|BLK1,126.15+19.07 (+1.72%) ▲|BMY68.09+0.43 (+0.64%) ▲|BNY164.33+2.29 (+1.41%) ▲|BRK-B508.13+2.89 (+0.57%) ▲|C138.14+3.80 (+2.83%) ▲|CAT800.14+7.86 (+0.99%) ▲|CL90.09-0.01 (-0.01%) ▼|CMCSA26.65-0.16 (-0.60%) ▼|COF220.50+3.90 (+1.80%) ▲|COP135.72-1.48 (-1.08%) ▼|COST925.41-3.07 (-0.33%) ▼|CRM264.43+7.50 (+2.92%) ▲|CSCO108.61-0.85 (-0.77%) ▼|CVS97.20-0.03 (-0.03%) ▼|CVX211.32-0.46 (-0.22%) ▼|DE694.41-3.96 (-0.57%) ▼|DHR211.03+1.12 (+0.53%) ▲|DIS107.16-0.82 (-0.76%) ▼|DUK121.40+0.84 (+0.70%) ▲|EMR150.21+1.23 (+0.83%) ▲|FDX324.31+7.77 (+2.45%) ▲|GD365.87+1.80 (+0.49%) ▲|GE333.48+3.98 (+1.21%) ▲|GEV941.84+19.90 (+2.16%) ▲|GILD151.22+1.61 (+1.08%) ▲|GM87.22+2.35 (+2.77%) ▲|GOOG339.08+5.30 (+1.59%) ▲|GOOGL342.48+5.36 (+1.59%) ▲|GS1,037.93+33.51 (+3.34%) ▲|HD318.07+1.89 (+0.60%) ▲|HON207.63+1.56 (+0.76%) ▲|IBM234.71+3.01 (+1.30%) ▲|INTC91.67+1.62 (+1.80%) ▲|INTU344.30+1.36 (+0.40%) ▲|ISRG369.83-2.05 (-0.55%) ▼|JNJ278.43+3.22 (+1.17%) ▲|JPM362.06+5.84 (+1.64%) ▲|KO88.81+0.57 (+0.65%) ▲|LIN482.19-3.66 (-0.75%) ▼|LLY1,159.60-0.48 (-0.04%) ▼|LMT532.95+1.40 (+0.26%) ▲|LOW201.90+2.06 (+1.03%) ▲|LRCX292.66+4.34 (+1.51%) ▲|MA585.71-2.43 (-0.41%) ▼|MCD259.63-1.32 (-0.51%) ▼|MDLZ61.45-1.00 (-1.60%) ▼|MDT93.10+0.92 (+1.00%) ▲|META610.68+17.83 (+3.01%) ▲|MMM168.31-0.44 (-0.26%) ▼|MO69.49-0.07 (-0.10%) ▼|MRK152.34+0.70 (+0.46%) ▲|MS217.15+5.33 (+2.52%) ▲|MSFT510.12+13.30 (+2.68%) ▲|MU958.16+2.08 (+0.22%) ▲|NEE84.06+0.96 (+1.16%) ▲|NFLX82.67-0.06 (-0.07%) ▼|NKE38.77+0.53 (+1.39%) ▲|NOW145.59+8.87 (+6.49%) ▲|NVDA228.45+4.04 (+1.80%) ▲|ORCL154.04+8.29 (+5.69%) ▲|PEP140.02-0.50 (-0.36%) ▼|PFE28.81-0.21 (-0.72%) ▼|PG146.92-0.72 (-0.49%) ▼|PLTR182.53+13.07 (+7.71%) ▲|PM186.17-1.77 (-0.94%) ▼|QCOM168.57-0.47 (-0.28%) ▼|RTX200.62-1.51 (-0.74%) ▼|SBUX105.89+0.07 (+0.07%) ▲|SCHW109.82-0.56 (-0.51%) ▼|SO88.78-0.03 (-0.03%) ▼|SPG211.95+0.44 (+0.21%) ▲|T26.18-0.01 (-0.02%) ▼|TMO618.43+9.89 (+1.63%) ▲|TMUS188.02+0.72 (+0.38%) ▲|TSLA376.37+19.36 (+5.42%) ▲|TXN257.46+3.63 (+1.43%) ▲|UBER76.63+0.67 (+0.88%) ▲|UNH398.39-2.56 (-0.64%) ▼|UNP289.85+0.71 (+0.25%) ▲|UPS103.00-0.51 (-0.49%) ▼|USB63.57+0.04 (+0.06%) ▲|V375.47-3.24 (-0.86%) ▼|VZ50.66+0.08 (+0.15%) ▲|WFC89.54+0.35 (+0.39%) ▲|WMT108.64+0.22 (+0.20%) ▲|XOM160.24-2.00 (-1.23%) ▼|AAPL328.21+3.25 (+1.00%) ▲|ABBV260.21-1.51 (-0.58%) ▼|ABT108.79-1.68 (-1.52%) ▼|ACN193.12+5.44 (+2.90%) ▲|ADBE285.75+5.96 (+2.13%) ▲|AMAT435.91-2.55 (-0.58%) ▼|AMD456.16-0.90 (-0.20%) ▼|AMGN444.12+1.28 (+0.29%) ▲|AMT177.75+4.83 (+2.79%) ▲|AMZN258.90+3.92 (+1.54%) ▲|AVGO357.16-10.08 (-2.74%) ▼|AXP329.82-0.16 (-0.05%) ▼|BA210.51+1.64 (+0.79%) ▲|BAC63.04+0.44 (+0.70%) ▲|BKNG195.13-4.47 (-2.24%) ▼|BLK1,126.15+19.07 (+1.72%) ▲|BMY68.09+0.43 (+0.64%) ▲|BNY164.33+2.29 (+1.41%) ▲|BRK-B508.13+2.89 (+0.57%) ▲|C138.14+3.80 (+2.83%) ▲|CAT800.14+7.86 (+0.99%) ▲|CL90.09-0.01 (-0.01%) ▼|CMCSA26.65-0.16 (-0.60%) ▼|COF220.50+3.90 (+1.80%) ▲|COP135.72-1.48 (-1.08%) ▼|COST925.41-3.07 (-0.33%) ▼|CRM264.43+7.50 (+2.92%) ▲|CSCO108.61-0.85 (-0.77%) ▼|CVS97.20-0.03 (-0.03%) ▼|CVX211.32-0.46 (-0.22%) ▼|DE694.41-3.96 (-0.57%) ▼|DHR211.03+1.12 (+0.53%) ▲|DIS107.16-0.82 (-0.76%) ▼|DUK121.40+0.84 (+0.70%) ▲|EMR150.21+1.23 (+0.83%) ▲|FDX324.31+7.77 (+2.45%) ▲|GD365.87+1.80 (+0.49%) ▲|GE333.48+3.98 (+1.21%) ▲|GEV941.84+19.90 (+2.16%) ▲|GILD151.22+1.61 (+1.08%) ▲|GM87.22+2.35 (+2.77%) ▲|GOOG339.08+5.30 (+1.59%) ▲|GOOGL342.48+5.36 (+1.59%) ▲|GS1,037.93+33.51 (+3.34%) ▲|HD318.07+1.89 (+0.60%) ▲|HON207.63+1.56 (+0.76%) ▲|IBM234.71+3.01 (+1.30%) ▲|INTC91.67+1.62 (+1.80%) ▲|INTU344.30+1.36 (+0.40%) ▲|ISRG369.83-2.05 (-0.55%) ▼|JNJ278.43+3.22 (+1.17%) ▲|JPM362.06+5.84 (+1.64%) ▲|KO88.81+0.57 (+0.65%) ▲|LIN482.19-3.66 (-0.75%) ▼|LLY1,159.60-0.48 (-0.04%) ▼|LMT532.95+1.40 (+0.26%) ▲|LOW201.90+2.06 (+1.03%) ▲|LRCX292.66+4.34 (+1.51%) ▲|MA585.71-2.43 (-0.41%) ▼|MCD259.63-1.32 (-0.51%) ▼|MDLZ61.45-1.00 (-1.60%) ▼|MDT93.10+0.92 (+1.00%) ▲|META610.68+17.83 (+3.01%) ▲|MMM168.31-0.44 (-0.26%) ▼|MO69.49-0.07 (-0.10%) ▼|MRK152.34+0.70 (+0.46%) ▲|MS217.15+5.33 (+2.52%) ▲|MSFT510.12+13.30 (+2.68%) ▲|MU958.16+2.08 (+0.22%) ▲|NEE84.06+0.96 (+1.16%) ▲|NFLX82.67-0.06 (-0.07%) ▼|NKE38.77+0.53 (+1.39%) ▲|NOW145.59+8.87 (+6.49%) ▲|NVDA228.45+4.04 (+1.80%) ▲|ORCL154.04+8.29 (+5.69%) ▲|PEP140.02-0.50 (-0.36%) ▼|PFE28.81-0.21 (-0.72%) ▼|PG146.92-0.72 (-0.49%) ▼|PLTR182.53+13.07 (+7.71%) ▲|PM186.17-1.77 (-0.94%) ▼|QCOM168.57-0.47 (-0.28%) ▼|RTX200.62-1.51 (-0.74%) ▼|SBUX105.89+0.07 (+0.07%) ▲|SCHW109.82-0.56 (-0.51%) ▼|SO88.78-0.03 (-0.03%) ▼|SPG211.95+0.44 (+0.21%) ▲|T26.18-0.01 (-0.02%) ▼|TMO618.43+9.89 (+1.63%) ▲|TMUS188.02+0.72 (+0.38%) ▲|TSLA376.37+19.36 (+5.42%) ▲|TXN257.46+3.63 (+1.43%) ▲|UBER76.63+0.67 (+0.88%) ▲|UNH398.39-2.56 (-0.64%) ▼|UNP289.85+0.71 (+0.25%) ▲|UPS103.00-0.51 (-0.49%) ▼|USB63.57+0.04 (+0.06%) ▲|V375.47-3.24 (-0.86%) ▼|VZ50.66+0.08 (+0.15%) ▲|WFC89.54+0.35 (+0.39%) ▲|WMT108.64+0.22 (+0.20%) ▲|XOM160.24-2.00 (-1.23%) ▼|
24.7 C
New York
Friday, September 4, 2026

Tag: gene therapy

newssourceFORcompanyinformationcontent1releasesmarket

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it has entered into a securities purchase agreement with Janus Henderson Investors, a global asset management firm, to purchase 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock at a purchase price of $1.00 per share (closing price on August 7, 2025) and accompanying warrant in a registered direct offering. The warrants have an exercise price of $1.50 per share, are exercisable immediately upon issuance, and will expire two years following the date of issuance. The warrants are callable by the Company when the VWAP of the Company’s common stock exceeds $2.50 per share for at least five of a trailing 30 trading day period. 

Sarepta Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion.

Investors can contact the law firm at no cost to learn more about recovering their losses

Cryoport Reports Second Quarter 2025 Financial Results

Second quarter revenue increased 14% year-over-year to $45.5 millionCommercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 millionLife Sciences Services revenue rose...

METiS Technologies Closes RMB 400 Million Series D Financing to Power Beijing’s Biopharmaceutical Innovation Engine

BEIJING, China, Aug. 4, 2025 /PRNewswire/ -- METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the successful completion of its RMB...

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT

NEW YORK, Aug. 03, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta and Petco and Encourages Investors to Contact the...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sarepta (SRPT) or PetCo (WOOF) To Contact Him Directly To Discuss Their Options

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 1, 2025, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 90,000 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

Xtalks Announces its Life Science Webinar Calendar for August 2025

Upcoming free, educational webinars from Xtalks will feature topics on cell and gene therapy, clinical trials, commercialization & HEOR, drug discovery & development, healthcare, laboratory...

Everads Announces Two Oral Presentations at ASRS 2025, Including Full Clinical Trial Results with Its Novel Suprachoroidal Injector

– Clinical study confirms safety, feasibility, and tolerability of the Everads Injector– – Preclinical data demonstrate the feasibility of in-office, minimally invasive suprachoroidal buckling using...

Hansa Biopharma announces key executive appointments to support continued growth

LUND, Sweden, July 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced three leadership appointments. Brian Gorman joins Hansa as...

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

The cell therapy market is anticipated to expand at a rapid pace owing to high incidence of chronic diseases, growing demand for novel treatments,...

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

The cell therapy market is anticipated to expand at a rapid pace owing to high incidence of chronic diseases, growing demand for novel treatments,...

Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight

No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic...

Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

VYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsGene therapy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers